<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02972918</url>
  </required_header>
  <id_info>
    <org_study_id>MML-LEV-2013-01</org_study_id>
    <nct_id>NCT02972918</nct_id>
  </id_info>
  <brief_title>Preoperative levosimendán and Hip Fracture</brief_title>
  <acronym>OPL</acronym>
  <official_title>Preoperative Optimization Levosimendan in Heart Failure Patients Undergoing Hip Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Canarias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario de Canarias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether preoperative optimization with levosimendan
      in heart failure patients undergoing hip fracture surgery improves haemodynamic and tissue
      perfusion parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hip fracture is a very predominant entity in elderly patients and it is one of the most
      frequent cause of admission in a hospital.

      Elderly patients undergoing surgery for hip fracture have a high risk of morbidity and
      mortality in the postoperative. Several studies have shown that there is a high risk of
      cardiovascular complications in this group of patients and 3-months mortality is 15-20%. One
      of the causes of this high morbidity and mortality is the high incidence of chronic cardiac
      failure in this patients. The goal of the present study is to evaluate if the optimization of
      preoperative cardiac function with levosimendan in patients with left ventricular ejection
      fraction &lt; 45% can improve haemodynamic and the tissue perfusion values, and reduce cardiac
      morbidity and mortality 3 months postoperatively.

      Following written consent, the patients with left ventricular ejection fraction &lt; 45% will be
      admitted in the resuscitation and anaesthesia room where they will receive a levosimendan
      intravenous injection undergoing a strict haemodynamic vigilance.

      Before the levosimendan intravenous injection the patients firs have an echocardiography to
      evaluate myocardial function, NT-proBNP. Subsequently, an arterial line is inserted and
      optimization achieved by using this arterial line connected to a ProAQT sensor system (
      PULSION , Edwards). The system uses pulse wave analysis to assess several parameters
      including: stroke volume index (SVI), cardiac index (CI), systemic vascular resistance index
      (SVRI), cardiac power index (CPI).The levosimendan will be administered like a continues
      injection during 24 hours (0,1 mcg/kg/min) without initial dose. Following the optimization
      the patients will be transferred to the operating room in the next 3 days and will come back
      to the resuscitation and anaesthesia room where they will stay 24 hours more if there is no
      any complication.

      All the cardiac complications will be documented and follw-up will be done by after 30 days
      and 3 months postoperative.

      The patients will be selected for more than 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effects of Levosimendan on left ventricular function.</measure>
    <time_frame>Baseline and every 24 hours postoperative, 48 h postoperative, and 7 days and after 30 days postoperative.</time_frame>
    <description>Changes of left ventricular function as assessed transthoracic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cardiac index</measure>
    <time_frame>48 hours after start of iv infusion</time_frame>
    <description>Measured through arterial pulse wave analysis. A baseline measurement is done before infusion is started</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in transport and tissue perfusion of oxygen</measure>
    <time_frame>1 to 2 day postoperative</time_frame>
    <description>measured by arterial and venous blood gases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in renal function</measure>
    <time_frame>1 to 7 days postoperative</time_frame>
    <description>Proportion of subjects who develop AKIN stage 1 (increase &gt; 0.3 mg/dl or &gt; 25% in serum creatinine from previous visit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NT-proBNP and troponin I</measure>
    <time_frame>24 hours postoperative, 48 h postoperative, 72 h postoperative, and 168 h postoperative</time_frame>
    <description>Plasma NT-proBNP levels were measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse.</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>Development of arrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse.</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>Occurence of nausea/vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse event.</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>Occurence of headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of high inotropes (dopamine, Norepinephrine)</measure>
    <time_frame>after 12 hours, after 48 hours and every 24 hours if still in the PO-Unit</time_frame>
    <description>during postoperative unit stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morbidity</measure>
    <time_frame>3 months</time_frame>
    <description>All cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>1st-30th postoperative day</time_frame>
    <description>Perioperative heart failure infarction, stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on mechanical ventilation</measure>
    <time_frame>1st-30th postoperative day</time_frame>
    <description>Perioperative heart failure infarction, stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>measured at 3 months</time_frame>
    <description>All cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative mortality</measure>
    <time_frame>7 days postoperative</time_frame>
    <description>All cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ventricular Dysfunction, Left</condition>
  <condition>Hip Fracture</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>At least 12 hours before surgery: Infusion of levosimendan (0,1 mcg/kg/min). 24 hours of infusion without a bolus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)</description>
    <arm_group_label>Levosimendan</arm_group_label>
    <other_name>Simdax.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients due to undergo urgent of hip fracture.

          2. Patients with cardiac failure (EF &lt; 45 %).

          3. Decompensated heart failure.

          4. Informed consent provided by the patient.

        Exclusion Criteria:

          1. &lt;18 years old

          2. Emergency surgery

          3. Serious aortic stenosis (&lt; 1 cm2)

          4. Sustained ventricular tachycardia or atrial fibrillation &gt;140

          5. Earlier episodes of &quot;torsades depointes&quot;

          6. Systolic blood pressure &lt; 85 mmHg

          7. Serious kidney failure (GFR &lt; 30 ml/min)

          8. Serious liver failure (known class C Child-Pugh score)

          9. Allergy levosimendan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María del Carmen Martín Lorenzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Canarias</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martín Lorenzo, MD</last_name>
    <email>mcmartin-lorenzo@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jorge Solera Marín, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>S/c Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magali González-Colaço Harmand, MD, PhD</last_name>
      <phone>+34 922675557</phone>
      <email>magaligch@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>ANA ALDEA, MD, PhD</last_name>
      <phone>+34922678115</phone>
      <email>a.aldea@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>María del Carmen Martín Lorenzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11(7):556-61.</citation>
    <PMID>11069188</PMID>
  </results_reference>
  <results_reference>
    <citation>Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999 Mar 13;353(9156):878-82.</citation>
    <PMID>10093980</PMID>
  </results_reference>
  <results_reference>
    <citation>Pedersen SJ, Borgbjerg FM, Schousboe B, Pedersen BD, Jørgensen HL, Duus BR, Lauritzen JB; Hip Fracture Group of Bispebjerg Hospital. A comprehensive hip fracture program reduces complication rates and mortality. J Am Geriatr Soc. 2008 Oct;56(10):1831-8. doi: 10.1111/j.1532-5415.2008.01945.x.</citation>
    <PMID>19054201</PMID>
  </results_reference>
  <results_reference>
    <citation>Ponschab M, Hochmair N, Ghazwinian N, Mueller T, Plöchl W. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair. Eur J Anaesthesiol. 2008 Aug;25(8):627-33. doi: 10.1017/S0265021508004080. Epub 2008 Apr 11.</citation>
    <PMID>18405408</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2016</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario de Canarias</investigator_affiliation>
    <investigator_full_name>María del Carmen Martín Lorenzo</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

